Comparison · NCT00484315-e2eabd02
TAXUS Element vs TAXUS Express: Target Lesion Failure (TLF) at 12 Months Post-index Procedure. TLF is Defined as Any Ischemia-driven Revascularization of the Target Lesion, Myocardial Infarction (Q-wave and Non-Q-wave), or Death Related to the Target Vessel.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. TAXUS Element vs TAXUS Express: Target Lesion Failure (TLF) at 12 Months Post-index Procedure. TLF is Defined as Any Ischemia-driven Revascularization of the Target Lesion, Myocardial Infarction (Q-wave and Non-Q-wave), or Death Related to the Target Vessel. Trial comparisons, record NCT00484315-e2eabd02. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00484315-e2eabd02
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0557 | 0.0426 | 0.0725 | wilson | |
| Risk in group 2 | 0.0615 | 0.0397 | 0.094 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00575 | -0.0408 | 0.0218 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.906 | 0.544 | 1.51 | log | |
| Odds ratio, group 1 over group 2 | 0.901 | 0.523 | 1.55 | log | |
| Number needed to treat, for one fewer participant with the outcome on TAXUS Element than on TAXUS Express | 174 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | TAXUS Element | Paclitaxel-eluting stent (PES) implanted using standard percutaneous coronary intervention (PCI) technique | 51 | 915 | OG000 |
| Group 2 | TAXUS Express | Paclitaxel-eluting stent (PES) implanted using standard percutaneous coronary intervention (PCI) technique | 19 | 309 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
Target Lesion Failure (TLF) at 12 Months Post-index Procedure. TLF is Defined as Any Ischemia-driven Revascularization of the Target Lesion, Myocardial Infarction (Q-wave and Non-Q-wave), or Death Related to the Target Vessel.
- Description
The number of participants who experience a TLF through 365 days post-procedure out of the participants who have either had a TLF within 365 days post-procedure or who were TLF-free with last follow-up at least 335 days post-procedure.
- Time frame
- 12 months post-index procedure
- Population
The primary analysis set for the non-inferiority testing of the primary endpoint, 12-month TLF, is the per protocol analysis set. All randomized participants who had the randomly assigned study stent implanted in the target coronary artery are included.
Source ClinicalTrials.gov
Trial
- Title
- TAXUS PERSEUS Workhorse
- NCT number
- NCT00484315
- Phases
- PHASE3
- Conditions
- Coronary Artery Disease
- Interventions
- Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation, Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement
- Lead sponsor
- Boston Scientific Corporation
- Results first posted
- 2011-06-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00484315?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00484315-e2eabd02